Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial
- PMID: 18834319
- DOI: 10.1086/592579
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial
Abstract
Background: Comparable sustained virologic response (SVR) rates have been documented between Asian patients who received 24 weeks of pegylated interferon (IFN) plus ribavirin and white patients who received 48 weeks of combination therapy for hepatitis C virus genotype 1 (HCV-1) infection. Whether a 48-week course of combination therapy shows a better SVR rate than a 24-week course of such therapy among Asian patients with HCV-1 infection has not been confirmed in multicenter, randomized studies.
Methods: In this multicenter, randomized trial, 308 treatment-naive HCV-1-infected Asian patients were randomly assigned to receive either 24 or 48 weeks of pegylated IFN-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy. The primary end point was SVR, defined as an undetectable serum HCV RNA level 24 weeks after discontinuation of therapy. In addition, rapid virologic response (RVR) was defined as an undetectable serum HCV RNA level at week 4 of therapy, and complete early virologic response was defined as an undetectable serum HCV RNA level at 12 weeks of therapy in the absence of RVR.
Results: By intention-to-treat analysis, patients who received 48 weeks of therapy had a significantly higher SVR rate than did those who received 24 weeks of therapy (76% vs. 56%; P < .001). Among patients with a baseline serum HCV RNA level <800,000 IU/mL and RVR, SVR rates were comparable between 24- and 48-week courses of therapy (94% vs. 100%; P = .13). In contrast, 48 weeks of therapy was associated with a significantly higher SVR rate than was 24 weeks of therapy among patients without RVR (39% vs.16%; P = .01) and among those who achieved a complete early virologic response (44% vs. 20%; P = .02).
Conclusions: In treatment-naive Asian patients with HCV-1 infection, 48 weeks of pegylated IFN-alpha-2a plus ribavirin therapy is associated with a higher SVR rate, compared with 24 weeks of such therapy. Patients with a baseline serum HCV RNA level <800,000 IU/mL and who have achieved an RVR can receive a 24-week course of therapy without compromising the SVR rates; however, those who have not achieved an RVR but who have achieved a complete early virologic response should receive a 48-week course of therapy.
Trial registration: ClinicalTrials.gov NCT00495131.
Similar articles
-
Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.Clin Drug Investig. 2008;28(1):9-16. doi: 10.2165/00044011-200828010-00002. Clin Drug Investig. 2008. PMID: 18081356
-
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.Int J Infect Dis. 2013 Nov;17(11):e1017-21. doi: 10.1016/j.ijid.2013.05.012. Epub 2013 Jul 27. Int J Infect Dis. 2013. PMID: 23896656
-
Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.World J Gastroenterol. 2016 Nov 21;22(43):9613-9622. doi: 10.3748/wjg.v22.i43.9613. World J Gastroenterol. 2016. PMID: 27920482 Free PMC article.
-
Treatment of chronic hepatitis C in Asia: when East meets West.J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. J Gastroenterol Hepatol. 2009. PMID: 19335784 Review.
-
Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.J Clin Gastroenterol. 2010 Sep;44(8):583-7. doi: 10.1097/MCG.0b013e3181d7a46c. J Clin Gastroenterol. 2010. PMID: 20375729
Cited by
-
Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment.Gastroenterology Res. 2014 Dec;7(5-6):123-130. doi: 10.14740/gr629e. Epub 2014 Dec 27. Gastroenterology Res. 2014. PMID: 27785282 Free PMC article.
-
Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.BMC Endocr Disord. 2019 Apr 5;19(1):36. doi: 10.1186/s12902-019-0362-7. BMC Endocr Disord. 2019. PMID: 30953492 Free PMC article.
-
Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?Cells. 2019 Apr 3;8(4):305. doi: 10.3390/cells8040305. Cells. 2019. PMID: 30987134 Free PMC article. Review.
-
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.Sci Rep. 2015 Nov 30;5:17410. doi: 10.1038/srep17410. Sci Rep. 2015. PMID: 26616669 Free PMC article.
-
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.BMC Gastroenterol. 2016 Jul 25;16(1):73. doi: 10.1186/s12876-016-0492-6. BMC Gastroenterol. 2016. PMID: 27457659 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical